Ellen Kurek

A lack of biomarkers can result in a delay in multiple sclerosis diagnosis and treatment.

The neurodegenerative phase of multiple sclerosis remains a significant challenge for researchers.

New FDA-approved drugs are members of a new class of vesicular monoamine transporter-2 inhibitors developed to address movement disorders.

FDA approval of valbenazine (Ingrezza) for the iatrogenic movement disorder tardive dyskinesia shows impact of a well-executed development program.

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in older people.

Dark adaptation testing has been shown to be better than visual acuity testing in diagnosing and staging AMD.

Study weighs whether aflibercept (Eylea) is cost-effective compared with ranibizumab (Lucentis) in treating diabetic macular edema.

Ranibizumab has been prescribed to treat more than 55,000 patients with diabetic macular edema.

Interstitial lung disease, a common complication of rheumatoid arthritis, often leads to deteriorating health.

Conflicting evidence surrounds the association between multiple sclerosis and uveitis.

Study shows a significant association between baseline foveal choroidal thickness and macular atrophy.

Anti-vascular endothelial growth factor agents are the criterion standard for diabetic macular edema.

Studies find varying results in incidence of strokes from wet age-related macular degeneration treatment.

Immunoregulatory agent sirolimus shows superiority to systemic corticosteroids in noninfectious uveitis.

Patients with severe refractory juvenile idiopathic arthritis-associated uveitis may achieve complete remission with tocilizumab.

Anti-vascular endothelial growth factor agents are the criterion standard for diabetic macular edema.

Healthcare resource use and costs related to eosinophil level in patients with asthma.

Once-daily tiotropium added to ICS maintenance therapy found safe and effective in moderate symptomatic asthma.